### Contents

#### Program Faculty
..............................................................................................................................................................

#### Sponsorship and CME Credit
.........................................................................................................................................................

#### CME Activity Assessment and Evaluation
.........................................................................................................................................................

#### Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference


- Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
  - Roman Perez-Soler

- HKI-272 in Non–Small Cell Lung Cancer
  - Kwok-Kin Wong

- Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
  - Mark A. Socinski

- Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
  - Daniel Morgensztern and Ramaswamy Govindan

- Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
  - Philip D. Bonomi, Lela Buckingham, and John Coon

- Bevacizumab in Non–Small Cell Lung Cancer
  - Alan Sandler

- Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
  - Emer O. Hanrahan and John V. Heymach

- Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
  - Gregory J. Riely and Vincent A. Miller

- Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
  - Bruce E. Johnson, David Jackman, and Pasi A. Jänne

- Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
  - Julie E. Bauman, Keith D. Eaton, and Renato G. Martins

- The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
  - Jeffrey A. Engelman

- Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
  - Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn

- Incorporating Bortezomib into the Treatment of Lung Cancer
  - Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara

- L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
  - Randeep Sangha and Charles Butts